Diamedica Therapeutics Inc (DMAC) 13F Holders & Ownership Data (91 Funds, Q2 2026)

DMAC ranks #4812 out of 37696 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

DMAC is a disclosed holding of Israel Englander (Millennium Management), one of the tracked superinvestors on AlphaSMO — it makes up 0.0% of that fund's own 13F portfolio.

91 institutions disclose a position in DMAC, but none treat it as a major bet — even Cooperman Leon G, its most concentrated holder, allocates just 0.7% of its own portfolio to it.

Blue Trust, Inc. has added to its DMAC position for two straight quarters, increasing it by $103.7K to reach $571.6K today.

DMAC is down 5.8% today, but institutions show net buying of $18.7M this quarter — a divergence between today's price move and the underlying institutional flow.

DMAC reported a net loss of $32.8M in its latest fiscal year.

• Not yet profitable — net loss of $32.8M in the latest fiscal year
• Net income declined year over year, from -$24.4M to -$32.8M
• Operating cash flow was negative, using $29.1M in cash
• Current ratio of 11.81x — enough short-term assets to cover short-term liabilities
• Liabilities run x equity — a highly leveraged balance sheet worth noting